ENTITY
SciClone Pharmaceuticals

SciClone Pharmaceuticals (SCICLONE HK)

108
Analysis
Health Care • China
SciClone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing pharmaceutical products for oncology and severe infection in Mainland China and internationally. Its portfolio includes proprietary product Zadaxin, used for hepatitis B, hepatitis C, and certain cancers, as well as in-licensed products like Zometa, DANYELZA, and Angiomax. The company was founded in 1990 and is headquartered in Shanghai, China.
more
bullish•Yidu Tech
•18 May 2021 10:26

HSCI Index Rebalance and Stock Connect: Potential Changes in June and September

A look at the potential changes to the HSCI at the June & September reviews and stocks that could be included in/excluded from Stock Connect. These...

Logo
751 Views
Share
bullish•Coupang
•14 Mar 2021 10:15

ECM Weekly (14th March 2021) - Coupang, Baidu, Shanghai Heartcare, Chaoju Eye Care, Linklogis, Tuya

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Share
•02 Mar 2021 12:11

SciClone (čµ›ē”ŸčÆäøš) IPO Trading: Bifurcation of Demand

We were bearish with the deal and with the recent correction in the market, we think there is a chance that the deal goes under water post listing.

Logo
452 Views
Share
bullish•Cheerwin
•28 Feb 2021 11:23

ECM Weekly (28 February 2021) - Cheerwin, Coupang, DDMP REIT, Aztech, Autohome HK

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Share
•22 Feb 2021 15:47

SciClone Pharmaceuticals IPO Valuation: Not Pleasing

SciClone has set the terms for its IPO, where it plans to issue approx. 116m shares at an indicative IPO price range of HK$17.2-18.8 per share to...

Share
x